The pancreas-brain axis: Insight into disrupted mechanisms associating type 2 diabetes and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 42, Issue 2, 2014, Pages 347-356

  Desai, Gauri S ^a   Zheng, Chen ^a   Geetha, Thangiah ^b   Mathews, Suresh T ^a   White, B Douglas ^a   Huggins, Kevin W ^a   Zizza, Claire A ^a   Broderick, Tom L ^c   Babu, Jeganathan Ramesh ^a  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY AT MONTGOMERY   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; amyloid ; insulin receptor; neurofibrillary tangle; type 2 diabetes

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE 1; GAMMA SECRETASE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; BLOOD BRAIN BARRIER; CONFORMATIONAL TRANSITION; DIABETIC PATIENT; DISEASE ASSOCIATION; EXTRACELLULAR SPACE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEGRADATION; INSULIN RELEASE; INSULIN RESISTANCE; NERVE CELL; NERVE CELL MEMBRANE; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE; BRAIN; METABOLISM; PANCREAS; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; DIABETES MELLITUS, TYPE 2; HUMANS; PANCREAS; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 84907873940     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140018     Document Type: Review

References (74)

1. Li L, Hölscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res Rev 56, 384-402.
2. Luchsinger JA, Tang M-X, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154, 635-641.
3. Ott A, Stolk R, Hofman A, Van Harskamp F, Grobbee D, Breteler M (1996) Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia 39, 1392-1397.
4. Kamal MA, Priyamvada S, ArivarasuNA, Jabir NR, Tabrez S, Greig NH (2014) Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. CNS Neurol Disord Drug Targets 13, 338-346.
5. Cholerton B, Baker LD, Craft S (2013) Insulin, cognition, and dementia. Eur J Pharmacol 719, 170-179.
6. Dai Y, Kamal MA (2014) Fighting Alzheimer's disease and type 2 diabetes: Pathological links and treatment strategies. CNS Neurol Disord Drug Targets 13, 271-282.
7. Gauthaman K, Pushparaj PN, Rajeshkumar M, Narasimhan K, Al-Qahtani M, Cheung NS, Manikandan J (2014)Common cellular and molecular mechanisms underlying Alzheimer's disease and type 2 diabetes: A knowledge-driven approach. CNS Neurol Disord Drug Targets 13, 247-258.
8. Haque R, Nazir A (2014) Insulin-degrading enzyme: A link between Alzheimer's and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 13, 259-264.
9. Alam Q, Haque A, Alam MZ, Karim S, Gan SH, Kamal MA, Jiman-Fatani A, Damanhouri GA, Abuzenadah AM, Aga C (2014) Nanotechnological approach in management of Alzheimer's diseases and type- 2 diabetes. CNS Neurol Disord Drug Targets. doi: 10.2174/1871527311312666 0159
10. C? aus?ević M, Farooq U, Lovestone S, Killick R (2010) Amyloid precursor protein and tau protein levels are differently regulated in human cerebellum compared to brain regions vulnerable to Alzheimer's type neurodegeneration. Neurosci Lett 485, 162-166.
11. Kienlen-Campard P, Octave J-N (2002) Correlation between -amyloid peptide production and human APP-induced neuronal death. Peptides 23, 1199-1204.
12. Vepsäläinen S, Hiltunen M, Helisalmi S, Wang J, van Groen T, Tanila H, Soininen H (2008) Increased expression of A degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology. Neurosci Lett 438, 216-220.
13. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
14. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283, 29615-29619.
15. Choy RW, Cheng Z, Schekman R (2012) Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid beta (Abeta) production in the trans-Golgi network. Proc Natl Acad Sci U S A 109, E2077-E2082.
16. Coburger I, Dahms SO, Roeser D, Guhrs KH, Hortschansky P, Than ME (2013) Analysis of the overall structure of the multi-domain amyloid precursor protein (APP). PLoS One 8, e81926.
17. Lemmin T, Dimitrov M, Fraering PC, Dal Peraro M (2014) Perturbations of the straight transmembrane alpha-helical structure of the amyloid precursor protein affect its processing by gamma-secretase. J Biol Chem 289, 6763-6774.
18. Neve RL, McPhie DL, Chen Y (2000) Alzheimer's disease: A dysfunction of the amyloid precursor protein. Brain Res 886, 54-66.
19. Gouras GK, Xu H, Jovanovic JN, Buxbaum JD, Wang R, Greengard P, Relkin NR, Gandy S (1998) Generation and regulation of beta-amyloid peptide variants by neurons. J Neurochem 71, 1920-1925.
20. Dislich B, Lichtenthaler SF (2012) The membrane-bound aspartyl protease BACE1: Molecular and functional properties in Alzheimer's disease and beyond. Front Physiol 3, 8.
21. Macias MP, Gonzales AM, Siniard AL, Walker AW, Corneveaux JJ, Huentelman MJ, Sabbagh MN, Decourt B (2014) A cellular model of amyloid precursor protein processing and amyloid-beta peptide production. J Neurosci Methods 223, 114-122.
22. Adwan L, Subaiea GM, Zawia NH (2014) Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers. Neuropharmacology 79, 596-602.
23. Atkin G, Hunt J, Minakawa E, Sharkey L, Tipper N, Tennant W, PaulsonHL(2014) F-box only protein 2 (Fbxo2) Regulates Amyloid Precursor Levels and Processing. J Biol Chem 289, 7038-7048.
24. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 31, 357-367.
25. Ryder J, SuY, Liu F, Li B, ZhouY, NiB(2003) Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun 312, 922-929.
26. Shiiki T, Ohtsuki S, Kurihara A, Naganuma H, Nishimura K, Tachikawa M, Hosoya K, Terasaki T (2004) Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci 24, 9632-9637.
27. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680.
28. Jiang S, Li Y, Zhang X, Bu G, Xu H, Zhang YW (2014) Trafficking regulation of proteins in Alzheimer's disease. Mol Neurodegener 9, 6.
29. Nishitsuji K, Tomiyama T, Ishibashi K, Ito K, Teraoka R, Lambert MP, Klein WL, Mori H (2009) The E693-mutation in amyloid precursor protein increases intracellular accumulation of amyloid oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am J Pathol 174, 957-969.
30. Nomura S, Umeda T, Tomiyama T, Mori H (2013) The E693Delta (Osaka) mutation in amyloid precursor protein potentiates cholesterol-mediated intracellular amyloid beta toxicity via its impaired cholesterol efflux. J Neurosci Res 91, 1541-1550.
31. Fernandez-Vizarra P, Fernandez AP, Castro-Blanco S, Serrano J, Bentura ML, Martinez-Murillo R, Martinez A, Rodrigo J (2004) Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. Histol Histopathol 19, 823-844.
32. Zheng L, Calvo-Garrido J, Hallbeck M, Hultenby K, Marcusson J, Cedazo-Minguez A, Terman A (2013) Intracellular localization of amyloid-beta peptide in SH-SY5Y neuroblastoma cells. J Alzheimers Dis 37, 713-733.
33. Bloom GS (2014) Amyloid-beta and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71, 505-508.
34. Lloret A, Badia MC, Giraldo E, Ermak G, Alonso MD, Pallardo FV, Davies KJ, Vina J (2011) Amyloidbeta toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J Alzheimers Dis 27, 701-709.
35. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS (2004) Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 88, 554-563.
36. Morris JK, Vidoni ED, Honea RA, Burns JM (2014) Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging 35, 585-589.
37. Qiu WQ, Folstein MF (2006) Insulin, insulin-degrading enzyme and amyloid- peptide in Alzheimer's disease: Review and hypothesis. Neurobiol Aging 27, 190-198.
38. Neumann KF, Rojo L, Navarrete LP, Farias G, Reyes P, Maccioni RB (2008) Insulin resistance and Alzheimer's disease: Molecular links & clinical implications. Curr Alzheimer Res 5, 438-447.
39. Pavlik V, Massman P, Barber R, Doody R (2013) Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis 34, 449-456.
40. Höppener JW, Lips CJ (2006) Role of islet amyloid in type 2 diabetes mellitus. Int J Biochem Cell Biol 38, 726-736.
41. Morales R, Moreno-Gonzalez I, Soto C (2013) Cross-seeding of misfolded proteins: Implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog 9, e1003537.
42. Shi J, Lepore N, Gutman BA, Thompson PM, Baxter LC, Caselli RL, Wang Y (2014) Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer's disease neuroimaging initiative study. Hum Brain Mapp. doi: 10.1002/hbm.22447
43. Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM (2012) Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J Exp Med 209, 2149-2156.
44. Luo J, Marechal JD, Warmlander S, Graslund A, Peralvarez- Marin A (2010) In silico analysis of the apolipoprotein E and the amyloid beta peptide interaction: Misfolding induced by frustration of the salt bridge network. PLoS Comput Biol 6, e1000663.
45. Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, Arbel-Ornath M, Betensky R, Davidson BL, Hyman BT (2013) Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med 5, 212ra161.
46. Petrlova J, Hong HS, Bricarello DA, Harishchandra G, Lorigan GA, Jin LW, Voss JC (2011) A differential association of Apolipoprotein E isoforms with the amyloid-beta oligomer in solution. Proteins 79, 402-416.
47. Götz J, Ittner L, Lim YA (2009) Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 66, 1321-1325.
48. Westermark P, Andersson A, Westermark GT (2011) Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 91, 795-826.
49. Young A, Denaro M (1998) Roles of amylin in diabetes and in regulation of nutrient load. Nutrition 14, 524-527.
50. Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, Aston-Mourney K, Carr DB, Westermark P, Westermark GT, Kahn SE, Hull RL (2011) beta-cell loss and beta-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178, 2632-2640.
51. Gotz J, Lim YA, Eckert A (2013) Lessons from two prevalent amyloidoses-what amylin and A have in common. Front Aging Neurosci 5, 38.
52. Jackson K, Barisone GA, Diaz E, Jin LW, Decarli C, Despa F (2013) Amylin deposition in the brain: A second amyloid in Alzheimer disease? Ann Neurol 74, 517-526.
53. Adler BL, Yarchoan M, Hwang HM, Louneva N, Blair JA, Palm R, Smith MA, Lee HG, Arnold SE, Casadesus G (2013) Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol Aging 35, 793-801.
54. Bachar-Wikstrom E,Wikstrom JD, Ariav Y, Tirosh B, Kaiser N, Cerasi E, Leibowitz G (2013) Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetes. Diabetes 62, 1227-1237.
55. Li Y, Xu W, Mu Y, Zhang JZ (2013) Acidic pH retards the fibrillization of human Islet Amyloid Polypeptide due to electrostatic repulsion of histidines. J Chem Phy 139, 055102.
56. Jha S, Snell JM, Sheftic SR, Patil SM, Daniels SB, Kolling FW, Alexandrescu AT (2014) pH dependence of amylin fibrillization. Biochemistry 53, 300-310.
57. Ma KC, Zhang EL, Ray Y, Wollenberg DG, Zagorski K, MG (1999) Residue-specific pKa measurements of the betapeptide and mechanism of pH-induced amyloid formation. J Am Chem Soc 121, 8698-8706.
58. Watve M, Bodas A, Diwekar M (2014) Altered autonomic inputs as a cause of pancreatic beta-cell amyloid. Med Hypotheses 82, 49-53.
59. Ritzel RA, Butler PC (2003) Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 52, 1701-1708.
60. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
61. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2, 1101-1113.
62. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Kustermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101, 3100-3105.
63. King MR, Anderson NJ, Guernsey LS, Jolivalt CG (2013) Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice. J Neurosci Res 91, 506-514.
64. Tokutake T, Kasuga K, Yajima R, Sekine Y, Tezuka T, Nishizawa M, Ikeuchi T (2012) Hyperphosphorylation of Tau induced by naturally secreted amyloid-beta at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3beta signaling pathway. J Biol Chem 287, 35222-35233.
65. Liu L, Martin R, Kohler G, Chan C (2013) Palmitate induces transcriptional regulation of BACE1 and presenilin by STAT3 in neurons mediated by astrocytes. Exp Neurol 248, 482-490.
66. Plattner F, Angelo M, Giese KP (2006) The roles of cyclindependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281, 25457-25465.
67. Sima AA, Li ZG (2006) Diabetes and Alzheimer's disease - is there a connection? Rev Diabet Stud 3, 161-168.
68. Morabito MV, Berman DE, Schneider RT, Zhang Y, Leibel RL, Small SA (2014) Hyperleucinemia causes hippocampal retromer deficiency linking diabetes to Alzheimer's disease. Neurobiol Dis 65, 188-192.
69. Reitz C (2012) The role of intracellular trafficking and the VPS10d receptors in Alzheimer's disease. Future Neurol 7, 423-431.
70. Messier C, Teutenberg K (2005) The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast 12, 311-328.
71. Heni M, Schopfer P, Peter A, Sartorius T, Fritsche A, Synofzik M, Haring HU, Maetzler W, Hennige AM (2013) Evidence for altered transport of insulin across the bloodbrain barrier in insulin-resistant humans. Acta Diabetol. doi: 10.1007/s00592-013-0546-y
72. Bingham EM, Hopkins D, Smith D, Pernet A, Hallett W, Reed L, Marsden PK, Amiel SA (2002) The role of insulin in human brain glucose metabolism: An 18fluoro-deoxyglucose positron emission tomography study. Diabetes 51, 3384-3390.
73. Duelli R, Kuschinsky W (2001) Brain glucose transporters: Relationship to local energy demand. News Physiol Sci 16, 71-76.
74. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, PasinettiGM(2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 28, 824-830.